Phase I/IIa safety and dosing trial of intrathecal AVXS 101 in patients with spinal muscular atrophy type 2

Trial Profile

Phase I/IIa safety and dosing trial of intrathecal AVXS 101 in patients with spinal muscular atrophy type 2

Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs AVXS 101 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jun 2017 According to an AveXis media release, this trial is expected to begin in the third quarter of 2017.
    • 21 Dec 2016 Planned initiation date changed from 1 Jul 2016 to 1 Apr 2017 as per an AveXis media release which states that the company expects to initiate this trial in the second quarter of 2017.
    • 18 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top